Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 108


Biomarkers for prostate cancer: prostate-specific antigen and beyond.

Duffy MJ.

Clin Chem Lab Med. 2019 Nov 12. pii: /j/cclm.ahead-of-print/cclm-2019-0693/cclm-2019-0693.xml. doi: 10.1515/cclm-2019-0693. [Epub ahead of print] Review.


How Precisely Can Prostate Cancer Be Managed?

Zhuang L, Johnson MT.

Int Neurourol J. 2016 Nov;20(Suppl 2):S120-130. Epub 2016 Nov 22. Review.


Genomic Markers in Prostate Cancer Decision Making.

Cucchiara V, Cooperberg MR, Dall'Era M, Lin DW, Montorsi F, Schalken JA, Evans CP.

Eur Urol. 2018 Apr;73(4):572-582. doi: 10.1016/j.eururo.2017.10.036. Epub 2017 Nov 10. Review.


Novel biomarkers and genomic tests in prostate cancer: a critical analysis.

Falzarano SM, Ferro M, Bollito E, Klein EA, Carrieri G, Magi-Galluzzi C.

Minerva Urol Nefrol. 2015 Sep;67(3):211-31. Epub 2015 Jun 9. Review.


The added value of percentage of free to total prostate-specific antigen, PCA3, and a kallikrein panel to the ERSPC risk calculator for prostate cancer in prescreened men.

Vedder MM, de Bekker-Grob EW, Lilja HG, Vickers AJ, van Leenders GJ, Steyerberg EW, Roobol MJ.

Eur Urol. 2014 Dec;66(6):1109-15. doi: 10.1016/j.eururo.2014.08.011. Epub 2014 Aug 26.


Prostate Health Index (Phi) and Prostate Cancer Antigen 3 (PCA3) significantly improve prostate cancer detection at initial biopsy in a total PSA range of 2-10 ng/ml.

Ferro M, Bruzzese D, Perdonà S, Marino A, Mazzarella C, Perruolo G, D'Esposito V, Cosimato V, Buonerba C, Di Lorenzo G, Musi G, De Cobelli O, Chun FK, Terracciano D.

PLoS One. 2013 Jul 4;8(7):e67687. doi: 10.1371/journal.pone.0067687. Print 2013.


Comparative assessment of urinary prostate cancer antigen 3 and TMPRSS2:ERG gene fusion with the serum [-2]proprostate-specific antigen-based prostate health index for detection of prostate cancer.

Stephan C, Jung K, Semjonow A, Schulze-Forster K, Cammann H, Hu X, Meyer HA, Bögemann M, Miller K, Friedersdorff F.

Clin Chem. 2013 Jan;59(1):280-8. doi: 10.1373/clinchem.2012.195560. Epub 2012 Dec 4.


Androgen Receptor Splice Variant 7 and Efficacy of Taxane Chemotherapy in Patients With Metastatic Castration-Resistant Prostate Cancer.

Antonarakis ES, Lu C, Luber B, Wang H, Chen Y, Nakazawa M, Nadal R, Paller CJ, Denmeade SR, Carducci MA, Eisenberger MA, Luo J.

JAMA Oncol. 2015 Aug;1(5):582-91. doi: 10.1001/jamaoncol.2015.1341.


Clinical utility of the prostate cancer gene 3 (PCA3) urine assay in Japanese men undergoing prostate biopsy.

Ochiai A, Okihara K, Kamoi K, Oikawa T, Shimazui T, Murayama S, Tomita K, Umekawa T, Uemura H, Miki T.

BJU Int. 2013 May;111(6):928-33. doi: 10.1111/j.1464-410X.2012.11683.x. Epub 2013 Jan 18.


Comparison Between the Four-kallikrein Panel and Prostate Health Index for Predicting Prostate Cancer.

Nordström T, Vickers A, Assel M, Lilja H, Grönberg H, Eklund M.

Eur Urol. 2015 Jul;68(1):139-46. doi: 10.1016/j.eururo.2014.08.010. Epub 2014 Aug 20.


Evaluation of New Tests and Interventions for Prostate Cancer Management: A Systematic Review.

Olleik G, Kassouf W, Aprikian A, Hu J, Vanhuyse M, Cury F, Peacock S, Bonnevier E, Palenius E, Dragomir A.

J Natl Compr Canc Netw. 2018 Nov;16(11):1340-1351. doi: 10.6004/jnccn.2018.7055.


A comparative performance analysis of total prostate-specific antigen, percentage free prostate-specific antigen, prostate-specific antigen velocity and urinary prostate cancer gene 3 in the first, second and third repeat prostate biopsy.

Auprich M, Augustin H, Budäus L, Kluth L, Mannweiler S, Shariat SF, Fisch M, Graefen M, Pummer K, Chun FK.

BJU Int. 2012 Jun;109(11):1627-35. doi: 10.1111/j.1464-410X.2011.10584.x. Epub 2011 Sep 21.


Prostate-Specific Antigen (PSA) Screening and New Biomarkers for Prostate Cancer (PCa).

Stephan C, Rittenhouse H, Hu X, Cammann H, Jung K.

EJIFCC. 2014 Apr 28;25(1):55-78. eCollection 2014 Apr.


Prostate health index and prostate cancer gene 3 score but not percent-free Prostate Specific Antigen have a predictive role in differentiating histological prostatitis from PCa and other nonneoplastic lesions (BPH and HG-PIN) at repeat biopsy.

De Luca S, Passera R, Fiori C, Bollito E, Cappia S, Mario Scarpa R, Sottile A, Franco Randone D, Porpiglia F.

Urol Oncol. 2015 Oct;33(10):424.e17-23. doi: 10.1016/j.urolonc.2015.05.032. Epub 2015 Jul 7.


Association of AR-V7 and Prostate-Specific Antigen RNA Levels in Blood with Efficacy of Abiraterone Acetate and Enzalutamide Treatment in Men with Prostate Cancer.

Qu F, Xie W, Nakabayashi M, Zhang H, Jeong SH, Wang X, Komura K, Sweeney CJ, Sartor O, Lee GM, Kantoff PW.

Clin Cancer Res. 2017 Feb 1;23(3):726-734. doi: 10.1158/1078-0432.CCR-16-1070. Epub 2016 Aug 3.


Prostate-Specific Antigen-Based Screening for Prostate Cancer: A Systematic Evidence Review for the U.S. Preventive Services Task Force [Internet].

Fenton JJ, Weyrich MS, Durbin S, Liu Y, Bang H, Melnikow J.

Rockville (MD): Agency for Healthcare Research and Quality (US); 2018 May.


AR-V7 in Peripheral Whole Blood of Patients with Castration-resistant Prostate Cancer: Association with Treatment-specific Outcome Under Abiraterone and Enzalutamide.

Seitz AK, Thoene S, Bietenbeck A, Nawroth R, Tauber R, Thalgott M, Schmid S, Secci R, Retz M, Gschwend JE, Ruland J, Winter C, Heck MM.

Eur Urol. 2017 Nov;72(5):828-834. doi: 10.1016/j.eururo.2017.07.024. Epub 2017 Aug 14.


The clinical effectiveness and cost-effectiveness of the PROGENSA® prostate cancer antigen 3 assay and the Prostate Health Index in the diagnosis of prostate cancer: a systematic review and economic evaluation.

Nicholson A, Mahon J, Boland A, Beale S, Dwan K, Fleeman N, Hockenhull J, Dundar Y.

Health Technol Assess. 2015 Oct;19(87):i-xxxi, 1-191. doi: 10.3310/hta19870. Review.


Urinary Prostate Cancer Antigen 3 as a Tumour Marker: Biochemical and Clinical Aspects.

Schmid M, Hansen J, Chun FK.

Adv Exp Med Biol. 2015;867:277-89. doi: 10.1007/978-94-017-7215-0_17. Review.


Supplemental Content

Support Center